Now could be a great time to put that cash to use toward an investment in these three Dividend Kings that could provide robust returns for a lifetime. Shares of AbbVie (NYSE: ABBV), Lowe's (NYSE: LOW), and Parker Hannifin (NYSE: PH) more than tripled over the past 10 years as investor confidence remained strong. AbbVie was spun off from Abbott Labs in 2013 as a research-based pharmaceutical business.
AbbVie (NYSE: ABBV) today announced that 27 abstracts across its gastroenterology portfolio will be presented at the Digestive Disease Week (DDW) Annual Meeting, May 21-24, 2022, in San Diego and virtually.
AbbVie (NYSE: ABBV) and Cugene Inc., a clinical-stage biotechnology company focused on developing next-generation precision immunology and oncology medicines to treat autoimmune disease and cancer, today announced an exclusive worldwide license option agreement for CUG252, a potential best-in-class Treg-selective IL-2 mutein, as well as other novel IL-2 muteins, for the potential treatment of autoimmune and inflammatory diseases.